Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Supportive Care in Cancer

Volumn 20, Issue 4, 2012, Pages 767-772

  Hardy, Janet ^a   Norris, Ross ^b   Anderson, Helen ^a   O'Shea, Angela ^a   Charles, Bruce ^c  

^a Department of Palliative and Supportive Care ^*  (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Drug monitoring; Noroxycodone; Oxycodone; Saliva

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; NOROXYCODONE; OPIATE; OXYCODONE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG RELEASE; DRUG SALIVA LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PH; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITATIVE RESEARCH; SALIVA; TANDEM MASS SPECTROMETRY; VEIN PUNCTURE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MORPHINANS; NEOPLASMS; OXYCODONE; PATIENT PREFERENCE; SALIVA; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 84863467704     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1147-3     Document Type: Article

References (38)

1. Mullangi R, Agrawal S, Srinivas N (2009) Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed Chromatogr 23:3-25
2. Michael C, Teichert J, Preiss R (2008) Determination of voriconazole in human plasma and saliva using high performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 865:74-80
3. Gallagher P, Leitch M, Massey A, McAllister-Williams R, Young A (2006) Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effect of collection method. J Psychopharmacol 20:643-649
4. Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, Pinguet F (2006) Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemother Pharmacol 58:292-305
5. Voultsios A, Kennaway D, Dawson D (1997) Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. J Biol Rhythms 12:457-466
6. Ruiz ME, Conforti P, Fagiolino P, Volonté MG (2010) The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results. Biopharm Drug Dispos 31:476-485
7. Gubala W, Zuba D (2003) Gender differences in the pharmacokinetics of ethanol in saliva and blood after oral ingestion. Pol J Pharmacol 55:639-644
8. Gorodischer R, Koren G (1992) Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring. Dev Pharmacol Ther 9:161-177
9. Gorodischer R, Burtin P et al (1997) Is saliva suitable for therapeutic monitoring of anticonvulsants in children: an evaluation in the routine clinical setting. Ther Drug Monit 19(6):637-642
10. Gandia P, Bareille M, Saivin S, Pavy Le-Traon A, Lavit M, Guell A, Houin G (2003) Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. J Clin Pharmacol 43:1235-1243
11. Ritschel WA, Parab PV, Denson DD, Coyle DE, Gregg RV (1987) Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. J Clin Pharmacol 27:647-653
12. Davis M, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84-92
13. Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K (2010) Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 70:78-87
14. Glare P, Davis M (2009) Oxycodone. In: Davis M, Glare P, Hardy JR (eds) Opioids in cancer pain, 2nd edn. Oxford University Press, Oxford, UK
15. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen D (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461-479
16. Andreassen TN, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O (2011) Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol. doi:10.1007/s00228-010-0948-5
17. Kirvela M, Lindgren L, Seppala T, Olkkola K (1996) The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13-18
18. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L (1997) Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 61:655-661
19. Lugo RA, Kern SE (2004) The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother 18(4):17-28
20. Edwards SR, Smith MT (2007) Low levels of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr 848:264-270
21. Quigley C, Joel S, Patel N, Baksh A, Slevin M (2003) Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side-effects in patients with cancer-related pain. Palliat Med 17:185-190
22. Cone E, Clarke J, Tsanaclis L (2007) Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J Anal Toxicol 31:424-433
23. O'Neal C, Crouch D, Rollins D, Fatah AA (1999) Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration. J Anal Toxicol 23:452-459
24. Pourzitaki C, Tachou H et al (2006) Heroin metabolites detection in saliva and blood. Rev Clin Pharmacol Pharmacokinet 20:108-109
25. Shiran M, Hassanzadeh-Khayyat M, Iqbal MZ et al (2005) Can saliva replace plasma for the monitoring of methadone? Ther Drug Monit 27:580-586
26. Kopecky E, Jacobsen S, Klein J, Bhushan K, Gideon K (1997) Correlation of morphine sulphate in blood plasma and saliva in pediatric patients. Ther Drug Monit 19:530-534
27. Skopp G, Pötsch L, Klinder K, Richter B, Aderjan R, Mattern R (2001) Saliva testing after single and chronic administration of dihydrocodeine. Int J Leg Med 114:133-140
28. Okura T, Hattori A, Takano Y, Sato T et al (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36(10):2005-2013
29. Yabuuchi H, Tamai I, Nezu J, Sakamoto K et al (1999) Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cation. J Pharmacol Exp Ther 289:768-773
30. Genter MB, Krishan M, Augustine LM, Cherrington NJ (2010) Drug transporter expression and localization in rat nasal respiratory and olfactory mucosa and olfactory bulb. Drug Metab Dispos 38:1644-1647
31. Thompson SJ, Koszdin K, Bernards CM (2000) Opiate-induced analgesia is increased and prolonged in mice lacking Pglycoprotein. Anesthesiology 92:1392-1399
32. Boström E, Simonssen USH, Hammarlund-Udenaes M (2005) Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 94:1060-1066
33. Hassan HE, Myers AL, Lee IJ, Coop A et al (2007) Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 96:2494-2506
34. Mercer SL, Coop A (2011). Opioid analgesics and P-glycoprotein efflux tranporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem (in press)
35. Uematsu T, Yamaoka M, Matsuura T, Doto R et al (2001) P-glycoprotein expression in human major and minor salivary glands. Arch Oral Biol 46(6):521-527
36. Kandimalla KK, Donovan MD (2005) Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosa. Pharm Res 22(7):1121-1128
37. Yamahara H, Lee VHL (1993) Drug metabolism in the oral cavity. Adv Drug Deliv Rev 12:25-40
38. Bosker W, Huestis M (2009) Oral fluid testing for drugs of abuse. Clin Chem 55(11):1910-1931